Role of new Immunophenotypic Markers on Prognostic and Overall Survival of Acute Myeloid Leukemia: a Systematic Review and Meta-Analysis
Role of new Immunophenotypic Markers on Prognostic and Overall Survival of Acute Myeloid Leukemia: a Systematic Review and Meta-Analysis
复制标题
DOI：
10.1038/s41598-017-00816-2
复制
发表时间：
2017-06-23
影响因子：
4.6
通讯作者：
Schimieguel, D. M.
中科院分区：
文献类型：
--
作者：
Costa, A. F. O.;Menezes, D. L.;Schimieguel, D. M.
尽管技术进步，但与其他血液系统恶性肿瘤相比，急性髓系白血病(AML)成人患者的预后和存活率仍然很低。免疫表型检测到的一些抗原可能很快对AML患者的病理生理、预后和总生存率(OS)起重要作用。因此，我们对PubMed、Scope us、Science Direct、Web of Science和Cochrane图书馆进行了系统的回顾和荟萃分析(使用Prisma指南)。我们分析了11项研究和13种抗原，通过639名患者的免疫表型检测。其中12例对急性髓系白血病的预后有负面影响。Meta分析显示AML标志物的高表达与10个月以上(RR 2.55；IC 95%；1.49-4.37)和20个月以上(RR 2.46；IC 95%；1.75-3.45)的生存率下降有关。知道免疫表型标记物的表达可能能够影响疾病行为看起来很有希望，这些标记物不是常规使用的。然而，它们一直与预后不良和存活率下降有关。这可能允许不同的化疗方案，包括未来对新治疗靶点的研究。
Despite technological advances, the prognosis and survival of acute myeloid leukemia (AML) adult patients remain low, compared with other hematologic malignancies. Some antigens detected by immunophenotyping may soon play a significant role in the pathophysiologic, prognostic, and overall survival (OS) rate of AML patients. Therefore, we conducted a systematic review and meta-analysis of PubMed, Scopus, Science Direct, Web of Science, and the Cochrane Library (using PRISMA guidelines). We analyzed 11 studies and 13 antigens, detected through the immunophenotyping of 639 patients. From them, twelve exhibited a negative impact with AML prognosis. The meta-analysis demonstrated a high expression of AML markers, which have been associated with a decrease in survival over 10 months (RR 2.55; IC 95%; 1.49-4.37) and over 20 months (RR 2.46; IC 95%; 1.75-3.45). Knowing that the expression of immunophenotypic markers, which are not used on a routine basis, might be able to influence disease behavior, looks promising. However, they have been associated with a poor prognosis as well as a decrease in survival. This may allow for different chemotherapeutical protocols, including future studies for new therapeutic targets.